3768-43-2

Basic information

• Product Name: 3-METHYLPIPERIDIN-2-ONE
• Synonyms: 3-METHYLPIPERIDIN-2-ONE;3-Methyl-2-piperidinone;2-piperidinone, 3-methyl-;3-Methyl-2-oxopiperidine
• CAS NO: 3768-43-2
• Molecular Formula: C₆H₁₁NO
• Molecular Weight: 113.16
• EINECS: 223-196-1
• Product Categories: Pyrans, Piperidines & Piperazines
• Mol File: 3768-43-2.mol

Chemical Properties

• Melting Point: 64-65
• Boiling Point: 211.9°C (rough estimate)
• Flash Point: 138.6°C
• Appearance: /
• Density: 1.0223 (rough estimate)
• Vapor Pressure: 0.0177mmHg at 25°C
• Refractive Index: 1.4580 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-METHYLPIPERIDIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYLPIPERIDIN-2-ONE(3768-43-2)
• EPA Substance Registry System: 3-METHYLPIPERIDIN-2-ONE(3768-43-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 3768-43-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-METHYLPIPERIDIN-2-ONE is used as a precursor in the synthesis of other chemical compounds, playing a crucial role in the development of pharmaceuticals. Its unique structure allows it to be a building block for the creation of bioactive molecules, contributing to the advancement of new drug formulations.
Used in Organic Synthesis:
As a reagent in organic synthesis, 3-METHYLPIPERIDIN-2-ONE is utilized for its ability to participate in various chemical reactions, facilitating the production of a wide range of chemical products. Its versatility in this context is a testament to its importance in the field of chemistry.
Used as a Solvent:
3-METHYLPIPERIDIN-2-ONE is also used as a solvent in different chemical reactions due to its properties that make it suitable for dissolving a variety of substances, thus aiding in the smooth progression of chemical processes.

InChI:InChI=1/C6H11NO/c1-5-3-2-4-7-6(5)8/h5H,2-4H2,1H3,(H,7,8)

Upstream product

• 626-56-2 3-Methylpiperidine 
• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 64-17-5 ethanol 
• 67-56-1 methanol 
• 37672-46-1 3-methyl-1-(phenylmethyl)-2-piperidinone 
• 356789-19-0 ethyl (trans)-5-[(t-butoxycarbonyl)amino]-2-methyl-2-pentenoate 
• 3430-17-9 2-bromo-3-picoline 
• 128773-73-9 N-(4-Methoxybenzyl)-δ-valerolactam 
• 29553-51-3 3-methyl-piperidine-2,6-dione 
• 89896-39-9 ethyl 5-azidovalerate 
• 14660-52-7 ethyl 5-bromovalerate 
• 179685-56-4 1-Aza-2-methoxy-3-methyl-1-cyclohexene 
• 5693-62-9 2,3,4,5-tetrahydro-6-methoxypyridine 
• 113789-89-2 5-Azido-2-methyl-pentanoic acid ethyl ester 

Downstream Products

• 23789-83-5 3,3-Dimethyl-2(1H)-piperidinone 
• 37672-46-1 3-methyl-1-(phenylmethyl)-2-piperidinone 
• 105-60-2 caprolactam 
• 1690-76-2 1,3-dimethyl-2-piperidinone 
• 150989-48-3 C₂₀H₂₃NO₂S 
• 185099-48-3 1,3-diphenylmethyl-3-methyl-2-piperidinone 
• 185099-47-2 3-ethyl-3-methyl-1-phenylmethyl-2-piperidinone 

Relevant articles and documents

Interrupted Pyridine Hydrogenation: Asymmetric Synthesis of δ-Lactams

Metal-catalyzed hydrogenation is an effective method to transform readily available arenes into saturated motifs, however, current hydrogenation strategies are limited to the formation of C?H and N?H bonds. The stepwise addition of hydrogen yields reactive unsaturated intermediates that are rapidly reduced. In contrast, the interruption of complete hydrogenation by further functionalization of unsaturated intermediates offers great potential for increasing chemical complexity in a single reaction step. Overcoming the tenet of full reduction in arene hydrogenation has been seldom demonstrated. In this work we report the synthesis of sought-after, enantioenriched δ-lactams from oxazolidinone-substituted pyridines and water by an interrupted hydrogenation mechanism.

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer, reducing inflammation and/or treating an autoimmune or inflammatory disease.

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

Carbazole-containing amides and ureas: Discovery of cryptochrome modulators as antihyperglycemic agents

A series of novel carbazole-containing amides and ureas were synthesized. A structure–activity relationship study of these compounds led to the identification of potent cryptochrome modulators. Based on the desired pharmacokinetic/pharmacodynamic parameters and the results of efficacy studies in db/db mice, compound 50 was selected for further profiling.

Directing Group in Decarboxylative Cross-Coupling: Copper-Catalyzed Site-Selective C-N Bond Formation from Nonactivated Aliphatic Carboxylic Acids

Copper-catalyzed directed decarboxylative amination of nonactivated aliphatic carboxylic acids is described. This intramolecular C-N bond formation reaction provides efficient access to the synthesis of pyrrolidine and piperidine derivatives as well as the modification of complex natural products. Moreover, this reaction presents excellent site-selectivity in the C-N bond formation step through the use of directing group. Our work can be considered as a big step toward controllable radical decarboxylative carbon-heteroatom cross-coupling.

CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

PROCESS FOR PREPARING LACTAMS

The present invention relates to a method for preparing lactams using heterogeneous catalysis by hydrogenating at least one compound of the following formula (I), where A is a radical of the following formula (I′) or (II′): —CH(R1)—CH(R2)— (I′); or —CH(R1)—CH(R2)—CH(R3)— (II′); where R1, R2 and R3 are, independently from each other, H, OH, an alkyl radical, or a cycloalkyl radical; and R is H or a straight or branched alkyl radical having 1 to 20, preferably 1 to 10, and more preferably 1 to 4 carbon atoms. Said method is carried out at a pressure of less than 60 bars, preferably 10 to 50 bars, in the presence of a solid hydrogenation catalyst including at least two metals selected from the group of noble metals and transition metals, and an inert substance used as a support, wherein said compound of formula (I) can be used alone or as part of a mixture.

Oxidant-free conversion of cyclic amines to lactams and H2 using water as the oxygen atom source

Direct conversion of cyclic amines to lactams utilizing water as the only reagent is catalyzed by pincer complex 2. In contrast to previously known methods of amine-to-amide conversion, this reaction occurs in the absence of oxidants and is accompanied by liberation of H2, with water serving as a source of oxygen atom. Formation of a cyclic hemiaminal intermediate plays a key role in enabling such reactivity. This represents an unprecedented, conceptually new type of amide formation reaction directly from amines and water under oxidant-free conditions.

An aza-enolate alkylation strategy for the synthesis of α-alkyl-δ-amino esters and α-alkyl valerolactams

Alkylation of the aza-enolate of valerolactim methyl ether with electrophiles affords α-alkyl lactims that may be hydrolysed under mild acidic conditions to afford their corresponding α-alkyl-δ-amino esters as their hydrochloride salts. Neutralisation of these salts with base results in smooth intramolecular cyclisation to afford their corresponding α-alkyl lactams in excellent yield. Georg Thieme Verlag Stuttgart.

Ring contraction of N-chlorolactams, a novel rearrangement

Upon photolysis in methylene chloride at -78 °C, different N-chlorolactams underwent a novel ring contraction to the corresponding carbamoyl chlorides, which were converted to the methyl carbamates. The rearrangement is 100% stereoselective, occurring with retention of configuration at the migrating carbon center. The yields of isolated carbamates ranged from 40% to 57%, the other product being the parent lactam, 18% to 38%.